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Tuberous sclerosis complex (TSC) is a genetically inherited condition that 
manifests with benign non-invasive tumours or hamartomas in multiple organ 
systems. The condition is of autosomal dominant inheritance with an 
estimated incidence of 1 in 6000 live births. Population based studies 
estimate the prevalence of TSC to be 1 per 14, 492 population.  
 
TSC has myriad presentations but 80 to 90% of these children have seizure 
disorders. The prevalence of learning disabilities in children with TSC ranges 
from 38% to 80%. Pervasive developmental disorders (PDD) and attention 
deficit hyperactivity disorder have been identified in half of the children with 
TSC. Cutaneous manifestations occur in more than 90% of TSC patients. 
Cortical tubers, cardiac rhabdomyomas and renal angiomyolipomas are other 
lesions associated with TSC in children.  
 
Currently TSC has no cure and associated complications manifest with 
advancing age. Parents are faced with the challenge of life long care for these 
children. Half of the parents of children with TSC suffer significant 
psychological stress. Child specific factors, health literacy, and social stability 
are some factors known to impact on parental understanding of a child’s 
chronic illness. Data specific to parental understanding of TSC are limited. 
 
Methodology  
A retrospective case note review was performed to obtain the patient 
demographic and clinical presentation data. A prospective observational study 
provided the parental background characteristics and information on their 
understanding of TSC. 
 
Results 
A total of 31 patient case notes were included in the review. The median 
patient age at the time of data was 132 months (IQR 96.00). The male: female 












Seizures were observed in 27 patients (87.1%). Infantile spasms were 
reported in 3 (9.6%) patients while partial seizures occurred in 11 (35.5%) 
patients. More than one anticonvulsant was required in 15 (48.4%) of the 27 
patients with seizures.    
 
Fourteen (53.8%) had global developmental delay. Two children (6.4%) were 
both hyperactive and aggressive and six (19.3%) were considered 
hyperactive. Aggressive behaviour was observed in four (12.9%) other 
children. 
 
Parents of 21 patients gave consent to participate in the study. The median 
parental age was 38 years (IQR 10.5). Seven parents (33.3%) had attained a 
primary level of education. Secondary education was attained by ten parents 
(47.6%) and three (14.3%) had received tertiary education. 
 
A statistically significant difference, p value =0.001, was observed in the 
change in the level of knowledge on comparison between the parent group 
that received a leaflet and the one that did not. A parental level of education of 
grade 8 was associated with a significantly higher baseline knowledge score 
(p value = 0.045) and a significantly greater change in the level of knowledge 
score (p value = 0.003).  
 
No association was detected between a parent’s duration of clinic attendance 
and the baseline level of knowledge (p value = 0.63) There was no 
association between a parents baseline level of knowledge and their 
assessment of the impact of TSC on their child. (p value = 0.61) 
 
Conclusions and recommendations 
The clinical profile of the cohort of children seen at the Red Cross Children’s 
Hospital is similar to that of other cohorts described in literature. Parental 
understanding of TSC can be improved by provision of written information for 
those with at least a grade eight level of education.  The information leaflet 














Tuberous sclerosis complex (TSC) is a genetically inherited condition that 
manifests with benign non-invasive tumours or hamartomas in multiple organ 
systems, mainly skin, central nervous system, heart, kidneys, eyes and lungs 
resulting in variable clinical presentations.1-4 The condition is of autosomal 
dominant inheritance and is one of the most common heritable single gene 
disorders in children with an incidence of 1 in 6000 live births 1-3 It is estimated 
that two thirds of new TSC patients without a family history are new 
mutations.
 
1,4 – 7.  
Population based studies are currently considered to provide the most 
accurate estimates of the prevalence of TSC.8 Initial studies conducted in 
1956 by Stevenson and Fischer in a population of Northern Ireland estimated 
the prevalence to be 1 per 150,000 population while that conducted by Singer 
in a Chinese population in 1971 estimated the prevalence to be 1 per 70,000 
population.8 Shepard and colleagues studied a population that included 
100,000 people in Olmstead County in Minnesota, USA and determined the 
prevalence of TSC to be 1 per 14,492 population.  Due to the comprehensive 
medical record system used, this study is considered to provide the most 
accurate estimation of the prevalence of TSC. 
 
8, 9. 
Patients with TSC may be identified at any age though historically the average 
age at presentation is five years.4 Indeed, earlier studies indicate many cases 
of TSC were only identified in late childhood and adulthood.4,10 With 
increasing awareness regarding the presentations of TSC,  improved 
availability of prenatal ultrasound, magnetic resonance imaging (MRI) and 
prenatal genetic testing the mean age at which a diagnosis of TSC is made is 
expected to reduce from the reported five years. 4,8,11,12
 
  
TSC has a myriad of clinical presentations that evolve with increasing age. At 
birth, many neonates with TSC may not be detected as the only external 
manifestation that may be present is hypomelanotic macules. 4,8,13 The most 











hypomelanotic macules and epilepsy. 4,12 Beyond infancy, seizure disorders 
are apparent in 80% to 90% of children with TSC.1-4, 6-13.
 
  
Approximately half of all patients with tuberous sclerosis have some degree of 
cognitive impairment.1-,3,6-8,10 Developmental, behavioural and sleep disorders 
are common in TSC cohorts with up to half of whom have autistic spectrum 
disorders.1-3,6,10,14-17. The age at which specific cognitive and behavioural 
problems present varies, with intellectual impairment evident before age three 
years, hyperactivity between three and eight years while anxiety and 
depression are commonly observed in adolescence.
   
15   
Parental perceptions on various chronic illnesses including epilepsy in 
children have been widely published but data from parents of children with 
TSC are few.18 It is known that parental understanding of a child’s chronic 
illness influences their ability to cope and their interaction with the health 
system.19-24  Further, it is known that parental perceptions of a child’s illness 
may in turn be influenced by factors such as the severity of a child’s illness as 
well as the stability of the parental social support systems. 
 
25-29. 
Currently TSC has no known cure. Active management of immediate 
problems with careful anticipatory evaluations for expected complications 
remains the mainstay of care for children with TSC. Data on African cohorts 
with TSC are limited and disease evolution in this part of the world has not 
been extensively studied.  This study would therefore make a useful 
contribution to the existing body of knowledge by providing a description of 
the Red Cross Children’s Hospital TSC cohort. An exploration of the 
understanding their parents have of this chronic condition would not only 
provide information but would also educate the health service providers on 


















Historical aspects of TSC 
 The earliest known graphic description of TSC dates back to 1835 in an atlas 
of skin diseases compiled by Pierre François Rayer in which a young man’s 
face is shown with small papules that bear the characteristic distribution and 
appearance of facial angiofibromas.8
 
  
In 1862 Friedrich Daniel von Recklinghausen described the pathological 
findings of a neonate who had died shortly after delivery. The post-mortem 
findings included multiple cardiac tumours and ‘cerebral scleroses’.1,8 A 
detailed report of the neurological presentation of TSC was first provided by 
Bourneville in 1880 when he described  a young girl who had presented with 
seizures and learning disabilities at the age of two years. This child was later 
found to have facial skin lesions and a spastic right hemiplegia in 




 Vogt in 1908 provided the frequently quoted triad of manifestations of TSC 
comprising of mental retardation, intractable epilepsy and adenoma 




In 1932 Critchley and Earl reported “white spots” (hypomelanotic macules) in 
29 patients with TSC and also described autistic behaviour as part of the 
condition.8 In 1942 Moolten recognized the complex pathological nature of the 
lesions that occur in this condition and named it “the tuberous sclerosis 
complex”, the name by which the condition is now known.8
 
  
The genetic nature of TSC was first elucidated by Kirpicznik in 1910, who 
reported a family with three generations of affected individuals and described 














The first genetic linkage analysis report that identified a probable TSC gene 
on chromosome 9q34 was published in 1987.8 The TSC1 gene was cloned 
and its product confirmed to be hamartin by van Slegtenhorst and colleagues 
in 1997. A second TSC locus (TSC2) was identified on chromosome 16p13 in 
1992 by Kandt and colleagues. This gene was cloned and its product 
confirmed to be tuberin in 1993 
 
8 
The genetic basis of TSC  
TSC is caused by a mutation in one of two tumour suppressor genes TSC1 
and TSC2 located on chromosomes 9 (9q34) and 16 (16p13) respectively.1,2,6-
8,30 Following identification of the TSC1 and TSC2 genes nearly 500 different 
mutations in these genes have been characterised.1,6,7,30 A mutation of one of 
these two genes is identified in 60 to 85% of TSC patients where resources 
allow genetic testing.1,7,11,31,32 A similar distribution of mutations of the TSC1 
and TSC2 genes has been described  among familial cases. Among sporadic 
cases TSC2 mutations are more frequent. 6,7,13,32
 
  
The TSC1 gene spans 50kb (kilobases) of genomic DNA and contains 23 
exons. It encodes the protein Harmatin which is widely expressed in normal 
tissue including brain, cardiac, skin and renal tissues.8,33,34 Several types of 
TSC1 mutations have been identified. Fifty percent are small deletions and 
insertions, 35% are nonsense mutations and less than 5% are large 
deletions.31,32,35,36. The exact function of Hamartin remains unknown but it 
forms a complex with tuberin which participates in cell cycle 
regulation.1,6,7,13,30,37,40-42. Most of the TSC1 mutations result in a truncated 
hamartin protein with loss of cell cycle regulatory function.
 
36 
The TSC2 gene spans 45 kb of genomic DNA and contains 42 exons.43 The 
gene is expressed in all normal adult tissues and encodes the protein tuberin 
which appears to participate in normal brain development and in removal of 














TSC2 mutations include large deletions and rearrangements in 15%, small 
deletions and insertions in 35% and nonsense mutations in 20%.31,32,45 These 
mutations result in loss of function.31,32,45  Whereas missense mutations have 
not been reported for the TSC1 gene they account for 25% of TSC2 gene 
mutations and do not cause loss of cell cycle regulatory function. 31,32,45-47.
 
  
Tuberous sclerosis is an autosomal dominant genetic disorder with complete 
penetrance. 1,4-8,48 It is estimated two thirds of new cases without a family 
history of TSC are new mutations within a family. 1,4-8,49-51. Two to ten percent 
of people who carry the TSC gene are not detected by genetic testing due to 




A loss of hetererozygosity for alleles of the TSC1 and TSC2 genes has been 
described in hamartomas from TSC patients. This observation indicates that 
two somatic mutations at a cellular level are required to produce the TSC 
phenotype. 1,30,37,52,53 Though penetrance of the mutant TSC gene is 
complete, the phenotypic expression of disease varies in individuals even 
within the same family due to somatic mosaicism.
 
54-57  
TSC1 mutations were previously reported to be associated with a milder 
neurological disease phenotype while TSC2 mutations were associated with 
more severe disease manifestations. 30-32,47,52,53 Subsequent studies have 
dispelled these initial findings, as both gene mutations have been shown to 
cause a similar clinical disease presentation.6,7,14,30,35,40,41,53
 
  
The variety of mutations that occur in each gene and the need for a second 
mutation in the wild type copy of the gene for expression of the pathogenic 
manifestations of TSC all contribute to the phenotypic variations observed in 
TSC.51,54-61. Clustering has not been observed to occur in TSC. The condition 















Pathogenesis of TSC 
The mammalian target of rapamycin kinase, (mTOR) is an enzyme which 
belongs to a family of phosphatidyl inositide kinases. mTOR kinase functions 
to promote protein translation and cellular proliferation under adequate 
nutritional and energy privisions.39  Harmatin and tuberin form an intracellular 
complex that inhibits mTOR. 1,6,7,13,30,37,38,43,47,52,53 mTOR in turn acts via Rheb 
(Ras homologue enriched in brain) an intracellular signalling protein to inhibit 
S6 kinase, a ribosomal protein that is key in the protein translation process, 




In normal cells with intact mTOR signalling, cell growth and proliferation 
proceeds in the presence of mitogens such as insulin, which activate the 
P13K (phosphoinositide 3-kinase) signalling system. The P13K system in 
turn, phosphorylates tuberin through protein kinase B (also known as Akt) and 
effectively inhibits the ability of the harmatin-tuberin complex to suppress 
mTOR activity.7,40,41
 
   
 A mutation in either TSC1 or TSC2 results in lack of either hamartin or 
tuberin therefore the hamartin – tuberin complex is not formed. Lack of this 
complex allows the cell proliferation cycle to be in a constant state of over 
activity due to lack of inhibitory regulation of mTOR mediated signalling to 




The process by which tuberin and hamartin control cell growth and 
proliferation is illustrated in the diagram below. (Permission to reproduce 













Model showing that tuberin-hamartin complexes modulate PI3K dependent signalling through 
mTOR to both 4E-BP1 and S6K1. Activation of PI3K leads to inactivation of the tuberin-
hamartin complex by Akt-mediated phosphorylation of tuberin at Ser-939 and Thr-1462. 
Inactivation of the tuberin-hamartin complex releases the inhibition of mTOR and allows 
nutrient-dependent signalling from mTOR to S6K1 and the 4E-BP1-eIF4E complex. As a 
result, cap-dependent and 5_terminal oligopyrimidine tract (5_-TOP) mRNA-mediated 
translation are increased. The dotted arrow depicts the finding that Akt phosphorylates mTOR 
(41). 
(Reference: Tee A.R, Fingar DC, Manning BD, et al, Tuberous sclerosis 
complex1 and 2 gene products functions, together to inhibit mammalian target 
of rapamycin (mTOR)-mediated downstream signalling. Proc Natl Acad Sci. 
2002; 99: 13571 – 13576.) 
 
The Harmatin-tuberin complex also participates in other pathways including a 
cell adhesion, cell migration and protein transportation pathways.7,8,52 It is 
postulated that loss of hamartin due to TSC1 mutations interferes with normal 











compromises cell migration. In the developing brain, loss of normal cell-cell 
interaction is thought to contribute to the formation of tubers.8
 
   
Diagnostic criteria for TSC  
The current diagnostic criteria for TSC were developed at a consensus 
conference held in 1998 that took into consideration all known specific 
manifestations of TSC and improved on previously utilised criteria.1,2,8,48
A definitive diagnosis of TSC is based on clinical features that are currently 
classified as major or minor features. Presence of two major features or one 
major and two minor features provides a definitive diagnosis of TSC, while 
presence of one major feature and one minor feature denotes probable TSC.
   
 
1,2,8,48 Detection of one major feature or two minor features indicates possible 
TSC. 1,2,8,48  Epilepsy is not considered one of the criteria due to it’s low 
specificity for TSC.2,48  
 
These criteria are summarised below. 




1. Facial angiofibroma or forehead plaque 
2. Non traumatic ungal or periungal fibroma 
3. Hypomelanotic macules (three or more) 
4. Shagreen Patches 
5. Multiple retinal nodular hamartomas 
6. Cortical tuber 
7. Subependymal nodule 
8. Subependymal giant cell astrocytomas 
9. Cardiac rhabdomyoma, single or multiple 
10. Lymphangiomyomatosis 
11. Renal angiomyolipomas 
Minor features 
1. Multiple randomly distributed pits in dental enamel 
2. Hamartomatous rectal polyps 
3. Bone cysts 











5. Gingival fibromas 
6. Non renal hamartomas 
7. Retinal achromic patch 
8. ‘Confetti’ skin lesions 
9. Multiple renal cysts 
Definite Tuberous sclerosis complex 
• Two major features or 
• One major and two minor features 
Possible Tuberous sclerosis complex 
• One major feature or 
• Two or more minor features 
 
Reference: Roach ES, Gomez MR. Tuberous sclerosis consensus 
conference: Revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624 
 
Due to the fact that many of the features of TSC appear with advancing age, 
the utility of the above criteria initially appeared to be limited in infancy.4,12,60.  
However, following the wide dissemination of these criteria, it is now known 
that  the criteria is of definite utility as it provides for a probable or a possible 




Following revision of the diagnostic criteria for TSC, recommendations for 
further evaluation of patients following  determination of a definite, possible or 
probable diagnosis of TSC were published in 1999.61  
 
These 
recommendations promote appropriate follow up, detection of complications 
















SUMMARY OF TESTING RECOMMENDATIONS.6
Assessment 
2 
Initial testing Repeat testing 
Neurodevelopmental 
assessment 
At diagnosis and school 
entry 
As indicated 
Ophthalmic examination At diagnosis and school 
entry 
As indicated 
ECG At diagnosis As indicated 
EEG If seizures occur As indicated 
Echocardiography If cardiac symptoms 
occur 
If cardiac dysfunction 
occurs 
Renal Ultrasound At diagnosis Children every 1-3 years 
Chest CT Adult females If pulmonary dysfunction 
occurs 
Cranial CT At diagnosis Children every 1-3 years 
MRI Brain At diagnosis Children every 1-3 years 
 
 
Reference: Roach ES, DiMario FJ, Kandt RS, et al. Tuberous sclerosis 
consensus conference: Recommendations for diagnostic evaluation. J Child 
Neurol 1999; 14: 401 – 407. 
 
The clinical presentation of TSC 
Dermatological features.  
Cutaneous manifestations occur in more than 90% of TSC patients, although 
none of them are pathognomonic.1,2,4,8,51,62,63 Hypopigmented lesions of 
varying shapes are common at birth and were found in 51% of infants at 
diagnosis in one study.4 They were found to increase in frequency from 89.6% 
in children below two years, to 97% in children 14 to 18 years in another 
study.4,12.  Webb et al examined a group of children under five years of age 
with TSC and found all of them to have hypomelanotic macules.63 
Hypomelanotic macules are commonly found on the trunk, extremities and 











lamp examination may be useful (though this examination was thought to be 
more useful for evaluation of adult relatives than children).64
 
  
Facial angiofibromas are smooth nodules that occur on the central part of the 
face, especially on the nasolabial folds, cheeks and the chin.1,2,8,12,37,48,65,66 
Facial angiofibromas are unique to TSC and are of diagnostic value in 
children with TSC in whom they appear between one and  years (52.8%). 




A fibrous plaque is a flesh coloured patch of raised skin of variable size and 
shape that is usually located on the scalp or forehead.1,2,8,12,37,48,66 These 
plaques appear at any age and may be evident at birth with a tendency to 
enlarge with advancing  age. 
 
8,60 
Connective tissue hamartomas, also known as shagreen patches, usually 
occur in the lumbosacral region at puberty in 48% of those with TSC.1,2,8,12,48 
The lesions are frequently elevated above the surrounding skin, asymmetrical, 
firm and resemble an orange peel. The number and size of Shagreen patches 
tends to increase into adulthood.
 
8  
Non-traumatic subungal or periungal fibromas are fleshy growths that occur 
around nail beds more frequently on the toes than on the fingers in 
approximately 20% of those with TSC at adolescence. 1,2,8,12,37,48,66
 
  
Confetti like lesions are multiple small white spots 1-2 mm in diameter that 
tend to occur over the forearms and lower legs. A higher incidence has been 
noted in adults (20%) than in children (2.8%).
 
8 
Neurological manifestations of TSC 
Epilepsy is the most common presentation in TSC and usually has an onset in 
childhood. Seventy percent of children have seizures before two years of 
age.1-4,6-13 It is estimated 80 – 90% of patients develop epilepsy at some point 















Patients with TSC exhibit multiple seizure types. Infantile spasms occur in a 
third to half of infants with tuberous sclerosis and are a common type of 
seizure at initial diagnosis. These seizures have a close association with 
learning disorders.1-4,6,8,12,69,70 Tuberous sclerosis is the cause of infantile 
spasms in 10 -20% of those who have this seizure type.
 
3 
 Infantile spasms among children with TSC have been found to be sensitive to 
Vigabatrin. Overall control of seizure disorders in children with TSC is a 
management challenge and often calls for additional interventions including 
surgery, and the ketogenic diet.1,4,6,8,12,30,37,39,67-74  The natural history of 
epilepsy in children with TSC tends to be one of progressive seizure 
frequency and severity.1,6,8,66 An attendant reduction in the quality of life is 
observed as a result of intractable seizures and adverse medication side 
effects.1,6,8,66  Seizure onset in infancy, presence of multiple seizure types and  
evolution of new EEG seizure foci are all poor prognostic factors. 6,8
 
  
Neuroimaging in children with TSC demonstrates cortical tubers, 
subependymal nodules and giant cell astrocytomas. 1-4,6,13,30,37,39,75-79 Cortical 
tubers are pathognomonic of the disease.1,36,75-79 Tubers are commonly found 
in the cerebrum, with 90% occurring in the frontal lobe while subependymal 
nodules occur in the walls of the lateral ventricles.1,75,79 Both CT and MRI 
scans can identify subependymal nodules but MRI fluid attenuated inverse 
recovery (FLAIR) sequences provide superior demonstration of brain 
abnormalities in TSC.1-3,6,30 Subependymal giant cell astrocytomas (SEGA) 
arise from subependymal nodules in 6 to 15% of subjects with TSC causing 
progressive neurological deficits. 
 
1,6,30,39,75,79 
The prevalence of learning disabilities in children with TSC ranges from 38% 
to 80% with those who have infantile spasm being the most affected. 1-3, 6-8, 
30,37,38,80,81 Patients with intractable seizure disorders and more than ten 











developmental outcomes.81,82 Cognitive disabilities in TSC range from mild 
learning disabilities to profound intellectual disability with the eventual 
outcome being influenced by the extent of the brain abnormality, age at 
seizure onset and type of seizure disorder.1,15,83
 
  
Children with cognitive disabilities are at particularly higher risk for 
behavioural and psychiatric disorders compared to those of normal 
intelligence. It has been observed 60 to 70% of children with both TSC and 
global intellectual impairment have one or more behavioural problems while 
only 20-30% of those with TSC without intellectual impairment have 
behavioural difficulties.28,84,85 Classical infantile autism has been identified in 
25% of those with TSC while pervasive developmental disorders (PDD) and 




Non-neurological manifestations of TSC 
Renal manifestations are the next most common presentation after 
neurological complications. Renal angiomyolipomas are present in up to 80% 
of TSC patients while renal cysts occur in less than 20%.1,8,51,89 
Angiomyolipomas exceeding four centimetres in diameter carry the risk of life 
threatening hemorrhage from dysplastic aneurismal vessels.1,8,30,89  Polycystic 
kidney disease (PKD) may also occur in TSC patients, reflecting a contiguous 
gene deletion syndrome. The PKD gene occurs adjacent to the TSC2 




Rhabdomyomas are the chief cardiac manifestation of TSC presenting in 50 
to 60 % of children with TSC. 1-4,8,11,89,90,91 They are easily detected prenataly 
with a maximal size at birth or in early childhood.1-4,8,11,90,91  Spontaneous 
regression during the first few years of life occurs.1,4,8,11,91 Majority of children 
with cardiac rhabdomyomas are asymptomatic. However, 2-4% of these 
children have large rhabdomyomas with resultant complications such as 













Ocular manifestations of TSC include retinal hamartomas, optic nerve 
atrophy, glaucoma, and colobomata of iris, lens and choroid.8 Retinal hypo-
pigmentation and hyper-pigmentation have also been reported.8 Depigmented 
lesions may have a plaque-like centre which obscures the choroidal blood 
vessels. Retinal hamartomas have been observed in approximately half of 
those with TSC, but visual disturbances are an uncommon presentation in this 
condition.1,2,8 Growth of retinal hamartomas is rare with most lesions 
remaining stable over several decades.1,2,8
 
  
Parental understanding of TSC and other chronic illnesses in children 
Parents of a child with a chronic illnesses are faced with the challenge of 
coping with the burden of daily care related to the illness and adjustment to 
the varying demands the condition places on them.19 Half of the parents of 
children with TSC, have been reported to have significant levels of 
psychological stress especially in relation to seizures, cognitive impairment, 
psychiatric and behavioural problems in their children.
 
18 
 Depression or concerns regarding signs, symptoms and diagnosis of chronic 
illness have been reported in parents.25-29,92-94 Some parents express concern 
regarding the effect of the child’s illness on their own functioning.38-42,89-91. In 
previous studies limitations in social and family function as a direct effect of 
the child’s illness have been reported.
 
18-20, 25-29, 93-95 
Single parents and parents experiencing significant difficulties that threaten 
family stability have been shown to perceive a child’s chronic illness as having 
a negative impact on the family.19,25 Greater family cohesion and marital 
stability avails support to parents. This reduces parental stress and improves 
their ability to cope with their child’s illness. 19,25 Whereas having a first degree 
family member with a similar illness helped children adapt to their condition 
the same effect was not observed in parents.25  
 
   
The severity of a child’s illness has an impact on parental perceptions of the 
child’s illness and satisfaction with the management of the condition. Parents 











compared to parents of children who required fewer interventions.18-21,25,28 
Parental understanding of the impact of chronic illness on the child and family 
is also influenced by non illness related factors such as a child’s age.25 Older 
children were perceived to have been more adversely affected by the onset of 
epilepsy more than younger children.
  
25 
Financial adjustment is a major concern among those with epilepsy and 
provision for the medical and social needs of such children contributes 
significantly to parental anxiety. These concerns may have an eventual 




Information regarding a patient’s chronic illness coupled with good 
communicative abilities of caregivers have been shown to contribute to 
positive patient perceptions regarding one’s illness and satisfaction with the 
care provided.20,28 The need for information was not related to the known 
duration of the patient’s illness but the duration of illness was related to the 
specific information a patient felt was relevant.20
 
  
Perceptions of health providers regarding the information needs and 
education of patients with chronic illnesses and their families is known to differ 
from that of parents and patients themselves.21,28,29 Providers tend to be 
concentrate on educating patients about the condition and expected 
outcomes while parents were more concerned about how the illness affected 
them or their child’s lifestyle. 21,28 Parental knowledge regarding management 
interventions is known to influence their perceptions regarding the well being 
of their children and the effectiveness of these interventions. 
 
28,29 
Parents place high value on information they receive from their health 
providers but the understanding of information provided is, in turn, partly 
dependent on one’s literacy level. 22-24,28 Health literacy has been described 
as “the degree to which individuals have the capacity to obtain, process and 















Numerous studies have shown that parental understanding of information 
provided regarding their child’s illness has a significant impact on a child’s 
health outcomes. Poor parental understanding has been associated with poor 
child health outcomes.22,97-100.
 
  Those who provide care for children with 
chronic illnesses such as TSC, therefore have an obligation to equip 
themselves with adequate knowledge and to convey information to the 
parents of these children using the most effective modes of communication in 




































To describe the clinical presentation and parental understanding of TSC at 
Red Cross Children’s Hospital.  
 
 SPECIFIC OBJECTIVES: 
1. To describe the clinical profile and disease evolution of a cohort of children 
with Tuberous sclerosis complex managed at Red Cross Children’s 
Hospital. 
2. To describe findings of specific investigations performed as part of 
diagnosis and management of TSC. 
3. To describe parental knowledge and perceptions regarding TSC. 
4. To determine the effect provision of educational material has on parental 
understanding of TSC. 
 
METHODS 
To fulfil the above objectives two studies were carried out.  
 
A. PATIENT STUDY 
Study design 
A retrospective case note review 
 
Subjects 
All patients with a confirmed diagnosis of TSC who had been enrolled at the 
Red Cross Children’s Hospital TSC service from January 1996 to December 
2008 were eligible for inclusion into the study. All patients that had complete 
identification data and clinical review notes were included. All patients with 
incomplete data were excluded.  
 
Measures 
Data were captured using a standardized form (Appendix 1) and eventually 
entered onto an Excel Microsoft word©
 












These included age, gender, ancestry and the anthropometric measures of 
height, weight and head circumference. A family history of seizures and or 
TSC was obtained as part of the background information. Ancestry as a 
demographic variable was recorded according to the Red Cross standard 
coding system which classifies patients into broad categories of African, 
Caucasian, Asian, mixed or other with an inclusion of the patient’s home 
language. The official languages recorded are Xhosa, Afrikaans and English 
with the rest denoted as other as these are the main languages spoken in this 
part of South Africa.101 An indicator of the patients social-economic back 
ground was obtained from the Red Cross hospital family income classification 




The diagnostic features of TSC that were recorded in patients medical records 
were classified as either major or minor features and a note made of the age 
at which they were first observed. Known conditions associated with TSC that 
were recorded in the folders were identified and recorded. These features 
included seizures, developmental delay, behavioural disorders, cardiac, and 
renal manifestations.  
 
Among patients with seizures, the age at onset, details of type and frequency 
of seizures were recorded. It is standard practice to have formal neuro-
developmental assessments for TSC patients in the pre-school age bracket at 
Red Cross Children’s Hospital. Details of these assessments were recorded. 
Where behavioural disorders were diagnosed, the formal behaviour clinic 
assessment outcome was recorded. Identified conditions associated with TSC 
that occurred in body systems other than the central nervous system were 
recorded when present. An ophthalmologist’s examination findings regarding 
visual function was also recorded.   
 
Interventions used for children with complications of TSC were recorded onto 











parents of children with severe disabilities. We recorded the proportion of 
children attending the TSC clinic who received these grants.  
 
Ethical considerations 
The protocol was submitted to the Red Cross Hospital Research Ethics 
Committee and to the University of Cape Town Committee for Human 
Research Ethics for review. Approval to conduct the study was granted. This 
being a review of data in patient folders, consent was not required. Data 
collected remained confidential and was not used in any way that allowed 
patient identification. This study adhered to the declaration of Helsinki of 
2000. 
 
B: PARENTAL STUDY 
Study design 
A prospective observational study 
 
Subjects 
One parent / legal guardian of each of the children with confirmed TSC and 
currently attending the service was eligible. Parents who withheld their 
consent to participate in the study were excluded. Failure in consistency of 




Data collection procedure. 
Prior to the start of the study an extensive literature search did not provide a 
suitable questionnaire that could be used to determine the level of knowledge 
parents have regarding TSC in children. A questionnaire (Appendix 3) was 
designed to determine the baseline knowledge that parents had regarding 
TSC. Possible responses to structured questions were included while some 
questions were open-ended. A score was of 0 to 4 was allocated to responses 
given to the structured questions. This score was not shown to parents during 
the data collection. A score of 0 was allocated for a wrong response while a 












Prior to the start of the study, each patient currently attending the TSC service 
was assigned a number from a table of random numbers. The patient group 
was then divided into two groups by random assignment. Changes in parental 
understanding of TSC were assessed during two clinic visits that were three 
months apart. Parents of children in the first group received an information 
leaflet on TSC after the first visit during the study period while parents in the 
second group received the information leaflet after the second visit. An 
adapted version of a parent information leaflet compiled by the TSC alliance 
was used to provide information to the parents. (Appendix 2). 
 
Questions that sought to establish the parental level of knowledge were based 
on the information in the leaflet provided. (Appendix 2) During questionnaire 
design, the use of phrases found in the information leaflet was avoided as 
much as possible to reduce chances of answers based on pattern recognition.  
 
Consent to participate in the study was obtained during routine, scheduled 
clinic visits while parents / legal guardians of children with TSC waited for the 
doctor to attend to them. Verbal explanation regarding the study was given. 
Following the explanation, written information was provided and read through 
with the parent to ensure understanding. (Appendix 3) All parents attending 
the TSC clinic during the course of the study understood spoken English. 
Written Xhosa and Afrikaans translations of the consent document and 
information leaflets were requested and provided for three of the parents.  
 
After the parent / legal guardian were satisfied with the information provided 
written consent was obtained. (Appendix 4) It was emphasized that 
participation in the study was voluntary and failure to participate would not 
affect their child’s standard of care in any way. Parents and guardians were 
informed of their freedom to withdraw from the study at any time and of the 
availability of the investigators to attend to any queries that they had. An 
interpreter was required on three occasions to interpret the questions into 













During the second clinic visit, other sources of information accessed in the 
interim by parents in both groups were recorded. Important knowledge gaps 




The demographic aspects of the parents that were recorded included age, 
gender, marital status, educational level, relationship to the child and 
ancestry. The duration of clinic attendance was determined  by recording the 
age at which the child first presented to the TSC service and the child’s 
current age.  
 
Parental level of knowledge 
Questions whose aim was to establish parental knowledge regarding TSC 
explored aspects such as diagnosis, aetiology, presentation and 
management. The first question sought an answer regarding the condition the 
child was on treatment for. This question was included in order to elicit 
whether parents understood that all symptoms observed were as a result of 
TSC.  
 
Parental perceptions of TSC 
Questions that sought to elicit parental perceptions regarding TSC revolved 
around their views on the impact TSC had on their own children’s lives, their 
major concerns regarding their child’s illness and the value of the TSC service 
to them and their families. 
 
Ethical considerations 
The study protocol was submitted to the Red Cross Hospital Research Ethics 
Committee and to the University of Cape Town Committee for Human 
Research Ethics for review. Approval to conduct the study was granted. 
Parental consent was sought by verbal explanation and provision of written 
information regarding the study. Where necessary interpretation into the 











written information. It was ensured that parents understood what the study 
involved before written consent was sought from them. They were informed 
that their participation in the study was totally voluntary and non participation 
would not in any way alter the care their children received. They were also 
informed the data would be kept confidential and not used in any way that 
allowed identification of an individual parent. At the end of the study all 
parents had received an information leaflet on TSC. This study also adhered 
to the declaration of Helsinki of 2000. 
 
STUDY SITE 
Red Cross Children’s Hospital is a government funded health facility located 
in the Western Cape Province of South Africa. It is a tertiary referral centre for 
the region. This province is inhabited by approximately 4.8 million people, 1.7 
million of whom are children aged 0 to 19 years. Approximately 23.7% of the 
population of the Western Cape Province is composed of people of African 
ancestry. Those of mixed descent comprise approximately 53.3% of this 




A tiered hospital bills system operates at Red Cross Children’s Hospital where 
charges for services are based on the combined family income. To this end 
patients are categorized from H0 to H3. Those in H0 group having no income 
and would usually qualify for government social grants. Families in H1 group 
have a combined family income of less than 50,000 Rand per annum while 
those in H2 category earn between 50,000 and 100,000 Rand per annum. 
Families in the H3 category earn more than 100,000 rand per annum.102
 
  
Patients from families in the H0 category and children below six years of age 
do not pay for services received at the hospital. Those in H1 class pay a flat 
rate of 35 Rand for a day’s service while those in H2 and H3 classes pay 50% 
















Normally-distributed data were summarised using mean (standard deviation, 
S.D), otherwise the median (interquartile range, IQR) was used. These results 
were presented in the form of charts and tables as applicable. Data were 
analysed using the χ2
 
 test, T-test, ANOVA test, Mann-Whitney U test, 
Wilcoxon paired test, or Kruskal Wallis test, whenever appropriate. Univariate 
and multi-variate models were fitted to determine strength of associations 
between exploratory variables and outcomes.  
All tests were two-sided. A p-value <0.05 was considered significant. Data 
were analyzed using the SPSS statistical package for social sciences™ 
Version 17.  
 
The statistical analyses performed included exploring the relationship 
between parental baseline level of knowledge and variables such as gender, 
age, marital status, educational level, ancestry, access to additional sources 
of information and duration of clinic attendance. An exploration for 
relationships between a change in the parental level of knowledge following 
administration of the information leaflet and the same variables was also 
included.  
 
Factors associated with parental perceptions regarding TSC were assessed 
by determining the relationship between the mean level of knowledge score of 
parents who gave specific responses and duration of clinic attendance, 




















1. Patient Demographic data 
 A total of 41 patient folders were registered into the TSC service from its 
inception. From these, 34 folders were available for analysis. Three of the 
available folders were excluded from the study due to incomplete data, 
leaving   31 for inclusion into the study.  
 
Children of African descent (12) accounted for 38.7% of the cohort while 
those of mixed descent (19) accounted for 61.3%. On evaluation of the 
complete case notes only 23 (74.1%) patients were currently attending the 
TSC service. Five (16.1%) had been transferred out to other services while 
three (9.6%) were lost to follow up. 
 
Age at presentation at the TSC clinic ranged from 2 to 156 months with a 
median of 36 (IQR 76.00) months. The patient age at the time of data 
collection ranged from 8 to 240 months, with a median of 132 months (IQR 
96.00).  
 
Presentation before one year of age was recorded in 10 (32.3%) cases, 
before the fifth birthday in 19 (61.2%) cases while the rest 2 (6.4%) presented 
after 5 years.  
 
The current body weight recorded ranged from 7.8 kg t 90 kg. The median 
body weight at the latest clinic visit for this cohort of children was 34 kg (IQR 
28.00). The height ranged from 170 to 68 cm. The median height was 134 cm 
(IQR 35.00).  
 
In this cohort nine (29%) patients were classified in economic class H0 while 
16 (51.6%) were placed in class H1. Six families were classified as economic 
class H2 or H3 accounted for 19.3% of the cohort.  At least half of the cohort 
16 (51.6%) children received monthly care dependency grants.  
 
As shown in Figure 1 below, there were 25 (80.6%) males and 6 (19.4%) 




























2. Clinical manifestations and management 
A median of three major characteristics (IQR 4.00) of TSC were recorded for 
each child with a range of one to seven major characteristics. Minor features 
were recorded in only eight patients with a median of one minor characteristic 
per patient. Figure 2 below shows the frequency of occurrence of specific 














































Figure 3 below summarizes the frequency of minor features of TSC recorded 
in the Red Cross Hospital cohort.  
 
Figure 3: Frequency of Minor features of Tuberous Sclerosis Complex. 
0 1 2 3 4

















A positive family history of seizures was reported by eight (25%) cases in this 
cohort, although only four (12.9%) children had a positive family history of 
TSC. 
 Table 1 below shows the proportions of patients with specific features of TSC 
in this cohort. 
 
Table 1: The Frequency of specific features of TSC observed in  
               this cohort. 
Feature of Tuberous 
Sclerosis 
Frequency Proportion of cohort   
(%) 
Facial Angiofibromas 19 61 
Hypopigmented Macules 19 61 
Shagreen Patch 10 32.2  
Fibrous Plaque 9 29.0 
Cortical tubers 10 32.2 
Subependymal nodules 20 64.5 
Giant cell astrocytomas 5 16.1 
Retinal Hamartomas 3 9.6 
Cardiac Rhabdomyomas 9 29.0 
Renal Angiomyolipomas 9 29.0 
Periungal fibromas 1 3.2 
Relative with TSC 4 12.9 
Retinal achromic patch 1 3.2 
Confetti skin lesions 2 6.4 




















Figure 4 below illustrates the mean ages at which features of Tuberous 
sclerosis were recorded.    
 
Figure 4: Mean patient age at feature presentation. 































In this cohort of children with TSC, a total of 11 (35.5%) children had renal 
manifestations of TSC. Two (6.4%) of these children had symptoms related to 
their renal complications, with complaints of right flank pain in one child and 
haematuria in the other. Clinical manifestations of cardiac involvement were 
recorded in one patient (3.2%) who had arrhythmia. 
 
 Ophthalmology evaluations were performed on 24 (77.4%) children in this 
cohort. Among these, four children (16.7%) had abnormal findings on 
fundoscopy. Three patients (12.5%) had mulberry-type retinal hamartomas 
and one also had retinal hypoplasia. The fourth (4.2%) patient had a semi 












Seizures were observed in 27 patients (87.1%). Infantile spasms were 
reported in three (11.1%) of these patients, while partial seizures occurred in 
11 (40.7%) of the patients with seizures. Generalized seizures were reported 
in 15 (55.5%) of patients with seizures. Two (7.4%) patients had more than 
one seizure type, where one presented with infantile spasms that later 
evolved into generalized tonic clonic type. The other had focal seizures as 
well as generalized tonic clonic seizures.  The median age at onset of 
seizures was 9 months, IQR 14.01 (range 2 to 135 months). Guardians of 
seven of the 27 patients (25.9%) were themselves known to have seizure 
disorders while one patient had a paternal grandfather with seizures.  
 
Good seizure control (no seizures) was reported for 16 (59.3%) patients. 
Eleven (40.7%) of the children with seizures were reported as having a 
seizure frequency that ranged from three times per week to once a month.  
 
Among those with ongoing seizures two (7.4%) were on one anticonvulsant, 
four (14.8%) patients were on two anticonvulsants while five (18.5%) patients 
were on three anticonvulsants.  
 
As shown in the Figure 5 below, 20 (74.1%) of the children with seizures 
received sodium valproate while 11 (40.7%) received clobazam. In addition, 
10 (37.0%) of these children received carbamazepine, four (14.8%) received 
lamotrigine while topiramate, clonazepam and phenytoin were all prescribed 
to one child only. More than one anticonvulsant was required in 15 (55.5%) of 





































Table 2 below shows the distribution of anticonvulsant use according to the 
seizure type. 
 
















3 14 3 20 
Clobazam 2 6 3 11 
Carbamazepine 0 2 8 10 
Lamotrigine 0 4 0 4 
Others 1   1 













None of the children had received epilepsy brain surgery, a vagal nerve 
stimulator or the ketogenic diet for seizure control.  
Neuro–developmental assessments were carried out on 26 (83.8%) patients. 
Fourteen (53.8%) of those assessed were found to have global 
developmental delay (median DQ score 50.4, IQR 10.4). Two (7.7%) of those 
assessed had delayed fine motor development and one (3.8%) had delayed 
speech development. Normal neuro–developmental assessments were 
recorded for 9 (34.6%) (mean DQ 92 SD 3.5) of those who had an 
assessment done.  
 
School placement data indicated 13 (41.9%) children in this cohort attended a 
mainstream school while seven (22.5%) were placed in a remedial class.  
Among the rest, three children (9.6%) attended a training school, three others 
(9.6%) attended a special care center and five families (16.1%) chose to keep 
their children at home. 
 
Behavioural disorders were not a concern amongst 19 (61.3%) children. 
Following behaviour clinic assessments, two children (6.4%) were found to be 
both hyperactive and aggressive, while six (19.3%) were considered 
hyperactive. Aggressive behaviour was observed in four (12.9%) other 
children but none of the children were thought to be depressed or to suffer 
from anxiety.  
 
One of the children who was both aggressive and hyperactive received 
risperidone as well as sodium valproate, clobazam and carbamazepine for his 
seizure disorder while the other was only on sodium valproate and 
carbamazepine. 
 
Neuro-psychiatric disorders were recognized in four (12.9%) children. A 
diagnosis of oppositional defiant disorder was made in two (6.4%) children 















As shown in Table 2 below, electroencephalograms (EEG) and computer 
tomography (CT) scans were the most frequent investigations performed in 
this cohort of patients.  
The frequencies of abnormal results detected by abdominal ultrasound, 
echocardiogram, CT scan and MRI of the brain have been summarized in 
Table 3. 
 
 Table 3.Frequency and results of investigations performed. 
Investigation Frequency 
No.              % 
Abnormal results 
No.                 % 
Electroencephalogram (EEG) 22                70.9 11                  50.0 
CT Brain 23                 74.2 23                100.0 
Abdominal Ultrasound 21                 67.7 11                  52.4   
MRI Brain 10                 32.2 10                100.0 
Echocardiogram 10                 32.2 5                    50.0 
Electrocardiogram (ECG) 2                     6.4 1                    50.0 
 
Eleven (50%) of the 22 EEG’s performed were abnormal. Five (45.5%) of the 
abnormal EEG’s showed focal discharges, three (27.3%) of the abnormal 
EEG’s had generalized spike and wave discharges and two (18.2%) showed 
generalized slowing. Two ECG’S were performed one of which detected 





















As shown in the figure 6 below, 28 (90.3%) of the patients had at least two 
types of investigations performed while 15 (48.4%) patients had at least three 
different types of investigations performed.  
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4. Parental demographic profile 
 
A total of 23 children currently attend the TSC clinic at Red Cross Children’s 
Hospital. Parents of 21 (91.3%) patients gave consent to participate in the 
study, 18 (85.7%) were female and three (14.3%) were male.  
 
The parental group had a median age of 38 years (IQR 10.5) with a range 
from 31 to 55 years. There were 14 (66.7%) married parents, Four (19.0%) 
were single and three (14.3%) were separated from their spouses. There 
were 14 (66.7%) parents of mixed descent and seven (33.3%) of African 
descent. 
 
All parents with the exception of one (4.7%) had received formal schooling 
while seven (33.3%) had attained a primary level of education. Secondary 
education was attained by ten parents (47.6%) and three (14.3%) had 












The mean duration of attendance at the TSC service for this group of parents 
was 86.19 months (SD 56.1) and ranged from 5 to 190 months.  
 
Baseline parental characteristics of those who had received a leaflet were 
compared with those of parents who did not receive an information leaflet. No 
statistically significant differences were detected. These findings are 
summarised in Table 4 below. 
 
Table 4: Comparison of parental background characteristics based on 
information leaflet distribution. 
Variable Received Leaflet  
No: 11 
Did not receive 
Leaflet No: 10 
p Value 
Mean Age (yrs) 39.00 41.3 0.41 
 
Gender No: (F) 

















level (grade 8) 








Mean duration of 
clinic attendance 
(months) 
92.09 79.70 0.62 
Ancestry (mixed) 






















5. Parental knowledge of TSC 
The first question that was administered, sought to explore if parents knew the 
condition for which their child was on treatment. Thirteen (61.9%) parents 
knew that their child had TSC while eight (38.1%) did not know.  
 
Two (9.5%) parents knew that TSC could be inherited and could also occur 
spontaneously while seven (33.3%) parents knew TSC was a heritable 
condition. A total of 12 (57.1%) parents did not know the cause of TSC. 
 
Twelve parents (57.1%) knew that a diagnosis of TSC was made by full 
clinical evaluation and investigations while four (19.0%) parents stated that a 
diagnosis of TSC could be made by physical examination. Five (23.8%) 
parents did not know how a diagnosis of TSC was made.  
 
Parental responses at the start of the study to the question that sought to 
establish which   investigations they knew could be done to make a diagnosis 
of TSC are summarised in Tables 5 and 6 below.  
 
Table 5: The number of investigations for TSC known to parents. 
Number of 
investigations  stated 
Number of parents Proportion (%) 
1 9 42.9 
2 7 33.3 
3 2 9.5 
4 3 14.3 

















Table 6 below shows the actual types of investigations that parents of children 
with TSC knew. 
 
Table 6: Types of investigations for TSC known to parents. 
Investigation Number of Parents          % 
MRI Brain /CT Brain 13                                 61.9 
Renal ultrasound 8                                   38.1 
Echocardiogram 2                                    9.5 
EEG 10                                47.6 
Wood’s Lamp 0                                     0 
 
 
Parental understanding of TSC manifestations was sought by asking them 
what organs or body systems were affected by TSC.  The brain, skin, kidney, 
heart and eyes were all identified as organs affected by TSC. Responses to 
this question are summarized in Table 7 below. 
 
 
Table 7: Number of body organs parents knew could be affected by TSC. 
Number of body organs Number of parents Proportion (%) 
1 8 38.1 
2 5 23.8 
3 5 23.8 
4 3 14.3 
Total 21 100 
    
 
That TSC is not a curable condition was known to 13 (61.9%) parents while 5 
(23.8%) thought it was curable. Three (14.3%) parents did not know whether it 














Five (23.8%) parents responded that there was nothing that could be done to 
help children with TSC live better with their condition while six (28.5%) 
parents stated giving medication was of benefit to children with TSC. Three 
(14.3%) parents felt that either giving medications or visiting the doctor were 
adequate interventions. Seven parents (33.3%) knew that giving medications 
and visiting the doctor to address the current problems and evaluate for new 
complications were suitable interventions.  
 
In response to a question that requested parents to list any problems that 
could be observed in children with TSC, all  except one parent included 
seizures in their responses. This particular parent stated there were no 
complications observed in these children as her one year old had cardiac 
rhabdomyomas that resolved at three months of age and his cortical tubers 
had not caused him any problems.  
Table 8 below summarizes the complications of TSC identified by parents. 
 
Table 8: Complications of TSC known to parents of children with TSC 
Complication Identified      No.                                % 
Seizures 20                                    95.2                                   
Behavioural problems 6                                       28.6 
Learning difficulties 7                                       33.3   
Inability to participate in school activities 4                                       19.0  
Inability to participate in social activities 3                                       14.3 
 
 
 A score was assigned to answers given in response to questions that sought 
to establish the level of parental knowledge.  The median score for the whole 
group of parents at the start of the study was 30 out of a possible total score 
of 87 points. The scores ranged from 16 points to 71 points, with a median 














Following the first visit 11 (52%) parents were given information leaflets to 
take home. (Appendix 2) On a subsequent visit, the same questionnaire was 
administered and a score assigned to the answers. The median score for the 
whole group on the second visit was 42 points (IQR 38.00). The median 
percentage change in the total scores for the whole group was 4.6% (IQR 
19.45).  
 
Table 9 below compares the recorded scores of parents who received 
information leaflets with those of parents who did not receive leaflets. 
 
Table 9: Change in parental level of knowledge following leaflet administration 
Variable 
 
Group of parents 
who 
Received Leaflet 
Group of parents 






34.2 39.2 0.97 
Second visit Mean 
score 
51.7 41.8 0.02 
Change  in level of 
knowledge 
20.1% 2.9% 0.001 
 
A statistically significant difference:  p value =0.001, was observed in the 
change in the level of knowledge on comparison between the parent group 
that received a leaflet and the group that did not. 
 
No statistically significant associations were observed between parental age, 
gender, marital status, ancestry or duration of a child’s illness and the level of 
knowledge either at the beginning of the study or at the subsequent visit. 
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Table 10: Factors associated with level of knowledge at baseline and second 
stage of study. 
Variable Association with 
initial score  
(p value) 
Association with %  
change in  
score  
(p value) 
Parental age 0.31 0.95 




Parental Ancestry 0.92 0.75 





A higher parental level of education had a positive association with an 
increase in the level of knowledge. Exploration for significance in changes in 
the level of knowledge was performed for the group as a whole and also 
based on the mean educational levels for the group. These findings are 
summarised in Table 11 below.   
 
Table 11: Association between the parental level of education and change in 
level of knowledge  
Variable Association 
 with  
baseline score 
(p value) 




















All parents cited the TSC service as their main source of knowledge regarding 
their child’s illness. Four (19.0%) parents indicated having received additional 
information from other clinical services within and outside of Red Cross 
Children’s Hospital and the internet. The difference in baseline knowledge 
score for this group of parent had no statistically significant difference when 
compared to that of parents who had no other source of information. [p value 
= 0.76] 
 
During the second visit we sought to establish if parents had accessed other 
sources of information other than that provided by the TSC service. Seven 
(33.3% %) parents had obtained information from other sources but the 
change in the level of knowledge in those who did compared to those who 
had no access to other sources of information on TSC was not statistically 
significant [ p value = 0.24]. 
 
6. Parental perceptions of TSC 
In response to a question that sought to establish the perceived extent to 
which parents felt TSC had affected the quality of their children’s lives, 13 
(61.9%) of parents felt the condition had  had a significant negative impact on 
their children. Three (14.3%) Parents felt that TSC had a moderate negative   
impact on the quality of their children’s lives while five (23.8%) felt TSC had 
not had any effect on the quality of their children’s lives.   
 
The mean baseline knowledge score for the parents who felt TSC had a major 
negative effect on their children was 37.5 (SD 15.6), that of those who felt the 
effect was moderate was 29 (SD 14.0) and that of those who felt TSC had 
had no effect was 41.2 (SD 21.2). The difference in the mean baseline 
knowledge scores of these three groups of parents was not statistically 
significant. [p value = 0.61] 
 
The change in the mean parental level of knowledge when the first and the 
second visit scores were compared had no statistically significant association 
with parental perception of the impact of TSC. [p value = 0.59] These findings 
















First visit  
No.        (%) 
Mean 
baseline 
score        
Second visit 
No.        % 
Mean  
second  
score          
Major impact 13           61.9 37.5         16           76.2 45.3         
Some impact 3             14.3 29            1              4.8 68            
No impact 5             23.8 41.2         4             19.0 48.2         
Total 21         100.0    21         100.0   
 
 
An assessment for association between the duration of a parent’s clinic 
attendance (as indicated by the known duration of a child’s illness) and an 
individual parent’s perception of the value of the clinic visit showed no 
statistically significant difference between those who felt it was useful 
compared to those who felt it was not useful. [p value = 0.13]  
 
Similarly, there was no statistically significant difference in the baseline level 
of knowledge between those who felt that visits to the clinic were useful 
compared to those who felt it was of no value. [p value = 0.81] 
 
Two (9.5%) parents at the beginning of the study felt that clinic visits had not 
been of much benefit to their children. The reason given by both of them was 
that their children had severe behavioural problems and this aspect had not 
significantly improved despite repeated visits.   
 
During the second visit only one (4.7%) parent perceived visits to the clinic to 
be of no benefit to her child to the lack of change in the child’s aggressive 
behaviour. Both parents had received an information leaflet.  
 
Table 13 below summarises the issues that were of greatest concern to 











The table also shows there were no statistically significant differences in the 
baseline level of knowledge and in the level of knowledge at the second visit 
on comparison between parents who raised a specific concern and those who 
did not.  
 
Table 13: Issues of concern to parents regarding TSC   
Issue of 
concern 
First Visit  





p value Second 
Visit 











12    57.1   40.3 0.82 18     85.7 48.6 0.18 




4      19.0   32.7 0.15 7      33.3 42.7 0.44 
Effect of the 
child’s 
illness on 
me as a 
caregiver 
0         0 0 0 3       14.3 32 0.18 
Cost of care 
/ medication 




At the first visit, 10 (47.6%) parents expressed concerns regarding only one of 
the major issues listed above. Three (14.3%) parents were worried about two 
specific issues while one (4.8%) parent was concerned about three issues. 












At the second visit, six (28.6%) parents cited one major issue of concern 
regarding their child while seven (33.3%) parents cited two major issues of 
concern. Five (23.8%) parents worried about three or more aspects of the 
condition while three (14.2%) parents had no major concerns. These findings 
are summarized in Figure 7 below. 
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There was no statistically significant difference in the total number of major 
concerns expressed when those who received a leaflet were compared to 
those who did not receive one. These findings are summarised in Table 14 
below. 
 
Table 14: Comparison of the number of major concerns between parents who 
received a leaflet and those who did not receive one  
Total number of 
concerns 
expressed   
Received 
information leaflet 




First visit 14 8 0.91 














  DISCUSSION 
 
Patient Clinical profile 
The Western Cape Province is inhabited by three major ancestral groups. 103 
 
The ancestral distribution of patients in this cohort does not mirror that of the 
inhabitant population as only the mixed and African ancestry groups are 
represented. This discrepancy may be due to the fact that Red Cross 
Children’s Hospital being a government facility is frequented by the lower 
income groups of the population. This observation is supported by the facts 
that majority (80.6%) of the patients in our cohort came from families in the H0 
and H1 categories, and over half (51.6%) of the families in this cohort 
received government income subsidies in the form of care dependency 
grants. 
Whereas a clear male predominance with a male to female ratio of 4:1 is 
noted in our data, this is not a uniform finding with some of the other studies 
reporting a higher frequency of female children. 
 
4,104 
A positive family history of Tuberous Sclerosis was recorded in only four 
(12.9%) of our patients. This finding is not unexpected as other studies also 
indicate that a family history of TSC is uncommon because at least two thirds 
of tuberous sclerosis patients have spontaneous mutations. 1, 4-7
 
    
All children in this cohort had definite TSC as they all fulfilled the diagnostic 
criteria that require presence of two major features.1-4,8,48  This is a useful 
finding in our context as genetic testing is neither available in South Africa nor 
fully reliable as only 60 to 80% of those who fulfill the diagnostic criteria have 
detectable mutations. 11,23,24 Two to ten percent of people who carry the TSC 
gene are not detected by genetic testing due to mosaicism.7
 
  
More than half of the children in our cohort had a diagnosis of TSC made 
before five years of age. This is in keeping with data from other studies that 
estimate the average age at diagnosis for children with tuberous sclerosis to 











prenatal ultrasound and diagnostic testing. 4,8,11
 
 That none of the children in 
our cohort had a prenatal diagnosis of Tuberous Sclerosis may be due to the 
previously low level of availability and utilization of prenatal ultrasound 
evaluation in South Africa.  
Hypopigmented macules have been reported in about 90% of children with 
TSC and usually appear in early infancy.1,2,4,8,63,66.
 
 Less than two thirds of the 
children in this cohort had this condition. This may be due to the fact that none 
of them had a wood’s lamp examination done as this would probably have 
identified more cases of hypopigmented macules. Hypopigmented macules 
had a mean presentation age of 22 months. The later presentation of this  
feature in our cohort could be related to the overall mean age of diagnosis of 
five years by which time guardians are likely to be unsure of the time when 
macules were initially noted. 
Facial angiofibromas usually appear by five years of age as small papules in 
the malar region. They increase in size and number becoming prominent by 
adolescence. 1,2,8,12,37,48,63,66 The recorded mean presentation age of 8 years 
for facial angiofibromas in the Red Cross cohort most probably represents the 
age at which the lesions became prominent and caused cosmetic related 
concerns  to the parents rather than the actual time of appearance.
 
37   
The median age of this cohort at the time of the study was 11 years and the 
recorded frequency of facial angiofibromas was 61%. Facial angiofibromas 
are usually observed in at least three quarters of children with TSC.1,2,8,12,37, 
51,64,67 
 
It is possible that the proportion of those with facial adenofibromas in 
our cohort was under-reported hence accounting for the lower proportion. An 
alternative explanation could be that children with TSC in this part of the world 
have a slower onset and progression of facial angiofibromas.      
Confetti lesions were recorded in only two patients and the age of 
presentation was recorded for only one patient (11years). This finding may not 











are known to appear much earlier and are present at birth in some cases. 
 
 
1,2,8,12,37,48,63,66   
Shagreen patches and periungal fibromas are lesions typically seen in about 
a third of adolescents with tuberous sclerosis. 1,2,8,12,37,48,63,66   A reported mean 
age of 10 years at presentation as noted in our cohort would be in keeping 
with findings from other studies. 1,2,48.   The incidence of retinal hamartomas 
ranges from 4 to 76 % with an increasing incidence observed with increasing 
age.8,102 The mean age at detection in this cohort was 10.5 years at which 
age the incidence is estimated to be 17.2%.8
   
 The reported incidence of 16.7% 
is in keeping with findings from other studies. 
Cardiac rhabdomyomas had a mean presentation age of 19 months in the 
Red Cross Children’s Hospital cohort. Cardiac rhabdomyomas are known to 
be present at birth hence the later mean age at presentation could be related 
to the mean age at diagnosis of five years by which time the indication for 
echocardiogram evaluation in an asymptomatic child was probably low. 
Cardiac rhabdomyomas are a common feature at initial presentation in 
infancy with frequencies of 90% reported in some series, and are known to 
resolve after infancy. 1,2,4,8,11,48,61,89
  
 The low frequency of cardiac 
rhabdomyomas (29%) could also be related to the low rate of echocardiogram 
evaluation (29%).      
Cortical tubers and subependymal nodules have been detected on prenatal 
imaging and before age two months postnatally.1,4,8,104.  The mean age at 
detection of 75 and 80 months respectively for these two lesions in this cohort 
most likely correlates with the time at which neuroimaging occurred and not 
the actual age at which these abnormalities developed. A mean age of seven 
years for detection of giant cell astrocytomas is also not in keeping with 
previous data and this finding may also be related to the later average age at 
presentation to the service. 1,4,8,104
 
 Low availability of MRI techniques 
necessary for detection of cortical tubers in our environment could also have 











Giant cell astrocytomas have been reported in 10% of infants and in 6 to 14% 
of children with TSC by early childhood.1,2,4,6,8,48 The frequency of 
Subependymal giant cell astrocytomas in the Red Cross Children’s Hospital 
cohort (16.1%) is similar to that reported in other studies.
 
 1,2,4,6, 8, 48.  
In a previous study, Magnetic resonance imaging (MRI) of the brain in infants 
showed cortical tubers and subependymal nodules in 93% and 88% 
respectively.4
 
 In the Red Cross Children’s Hospital cohort, subependymal 
nodules were reported in almost two thirds of the patients (64.5%) while 
cortical tubers had a frequency of 32.2%. These frequencies of subependymal 
nodules and cortical tubers correlate closely with the frequencies of CT scan 
Brain (74.2%) and MRI brain studies (32.2%) performed on this cohort. This 
observation can be explained by the fact that calcified subependymal nodules 
are adequately detected by Computer tomography (CT) scan of the brain 
while cortical tubers are better detected by MRI brain studies.  
Renal angiomyolipomas occur in 70% to 80% of children older than 10 years 
who have TSC. 2,48,89 
 
The mean age at detection of renal angiomyolipomas in 
our study was 10 years. This finding was reported in only 9 (29%) of these 
children though an abdominal ultrasound was performed on 21 (67.7%) 
children. It is therefore plausible that the rate of angiomyolipoma development 
in South African children with TSC differs from that in other populations. 
However it is difficult to draw firm inferences due the small numbers of 
children detected to have angiomyolipomas.  
Symptoms arising from the presence of renal angiomyolipomas are rarely 
observed before the third decade of life and tend to be observed in 
adolescents and adults.8
 
 The two children with angiomyolipomas who were 
symptomatic in this cohort were aged 14 and 16 years, which is in keeping 
with findings from previous studies. 
Seizures are a common presenting feature in infancy and overall 80% to 90% 
of all children with TSC develop epilepsy. 1-4, 6-11,13 The frequency of 87.1% 











studies. The range of age of onset is also unremarkable and in keeping with 
that reported in other studies. Intractable seizures occurred in nine (33.3%) of 
those with seizures. It is a well recognized fact that intractable seizures are 
common in children with TSC but the estimated prevalence is not well defined 
in literature. 6,30,37,71 
 
  
Sodium valproate which is recommended for generalized epilepsies was the 
most commonly prescribed anticonvulsant with a 64% utilization rate. This 
was appropriate therapy as generalized and complex seizure disorders were 
observed in more than half (66.6%) of those with epilepsy in this cohort. 
Vigabatrin is particularly useful in patients with infantile spasms and TSC. 
1,8,37,71 It is notable that despite the fact that three (11.1%) of the patients had 
infantile spasms none of them received vigabatrin. Two of these three patients 
are now well controlled and the third has a generalized tonic clonic seizure 
once or twice a month. 
 
  
Cortical tubers and other TSC related brain malformations may form foci for 
partial seizures.4,6,37,71 Carbamazepine is the anticonvulsant of choice for 
these form of seizures while clobazam, lamotrigine, and topiramate are added 
as second line agents if there is suboptimal response to  carbamazepine.1,8,71. 
 
These treatment guidelines were followed in the management of partial 
seizures in the Red Cross cohort. Eleven children had partial seizures, eight 
of whom were on carbamazepine.  Additional anticonvulsants agents were 
required for seizure management for four of these eight patients. 
Early descriptions of TSC by scientists such as Voigt and Bourneville included 
mental retardation but it is currently known only approximately half of those 
with TSC have cognitive disabilities.1-3,6-8,15,16,37
 
 Our results are in keeping with 
those of other studies as 53% had global developmental delay and 58.1% 
needed alternative placement as they could not attend a mainstream class. 
One patient in our cohort had autism and infantile spasms that evolved into a 
complex partial seizure disorder that was well controlled. He also had severe 











institution. It is estimated that the prevalence of autism and pervasive 
developmental disorders in children with both intellectual disability and TSC is 
three times greater than that in those without both co-morbidities. Infantile 
spasms are also considered a risk factor for the development of autism.
 
14,17 
An Electroencephalogram study (EEG) were performed for 22 (70.9%) 
children and half of them were reported as abnormal. It is estimated that 75% 
of all patients with TSC will have abnormalities on EEG, 48% of which have 
focal and multifocal discharges and 8% have generalized spike and wave 
abnormalities.80 Similar findings are noted from our EEG recordings with 45% 
of abnormal EEG’s showing focal discharges. However a higher proportion 
(27.3%) of generalized spike and wave abnormalities was observed in our 
study compared to that reported by Gomez.
 
80 
Assessment of parental level of knowledge.  
The Red Cross Children’s Hospital service was the only source of information 
regarding TSC for majority (83.6%) of the parents interviewed. This fact 
highlights the importance of providing parents with adequate information in 
addition to the clinical service on an ongoing basis. From previous studies it is 
known that patients attach great value to information given by their health 
providers regarding their condition.20
 
  
The known duration of illness which equated to the duration of attendance at 
the clinic had no association with the level of knowledge a parent had at the 
beginning of the study. This fact may indicate a lack of additional education 
and reinforcement of an understanding of TSC beyond the initial counseling. 
Previous studies have demonstrated that patients’ need for education 




More than half of the parents knew that their child was on treatment for TSC 
and understood how a diagnosis was made. They also knew the 
complications and manifestations of TSC and the fact that TSC is not a 











understood may be due to the fact that this is a particularly difficult concept for 
non medically trained people to understand. It has been observed previously 
that the complexity of a clinical concept may influence the patient’s ability to 
understand the facts presented though this may also be influenced by a 
health provider’s communication skills22
 
   
One fifth of the parents interviewed felt that there was not much that could be 
done for patients with TSC. This perception was probably due to the observed 
chronicity of the condition and persistence of complications in their own 
children. Indeed, three of the five parents who gave this response had 
children with intractable seizures and one had a child with a behavioral 
disorder. 
 
It is important to note that a statistically significant difference in the baseline 
level of knowledge was not detected between the parents who received an 
information leaflet when compared to those who were not issued with one at 
the end of the first clinic visit. 
 
 Provision of an information leaflet was associated with a statistically 
significant difference in the change in parental level of knowledge when those 
who received a leaflet were compared to those who did not. [p value =0.001] 
This observation indicates that provision of written information is a useful way 
of improving parental understanding of their child’s condition. 
 
A significantly greater change in the level of knowledge was observed among 
parents who had at attained a secondary school level of education (grade 8). 
A higher level of education would equip one better with the ability to 
understand written information and could also be a motivating factor for one to 
actually read the information provided.22 Low literacy skills have been shown 




The TSC service was the main source of information for this group of parents. 











significantly to their level of knowledge. This finding as observed in other 
studies, serves to underscore the importance of provision of education by 
clinicians who care for patients with chronic conditions such as TSC.21,22
     
    
Parental perceptions regarding TSC  
Parental level of knowledge as indicated by the baseline and second scores 
had no correlation with parental understanding of the impact of TSC on their 
child’s life. This finding contradicts findings from other studies which suggest 
that the parental level of knowledge determined the parent’s perceptions 
regarding the child’s illness.29
 
  
It is notable that children of three of the five parents who felt TSC had little or 
no effect on the quality of the child’s life had well controlled seizure disorders 
while two children had not ever had seizures. None of the five children had 
pervasive developmental disorders. It is very likely that parental assessment 
of the effect of TSC on a child was based on parental assessment of the 
child’s functional level and not the actual complications the child had. 
Rodenburg and Morrow have previously shown that parental perception of a 
child’s illness had a positive correlation to the severity of the child’s illness.19,28
 
  
Two parents (9.5%) felt that the clinic visits had not been useful. One of the 
children had global developmental delay, attention deficit hyperactivity 
disorder and an Autistic spectrum disorder. The other child had seizures an 
oppositional defiant disorder, and aggressive behaviour.  These were the only 
children in the cohort that required risperidone and methylphenidate as part of 
their management. Behavioural problems in children with complex seizure 
disorders and learning disabilities are particularly difficult to manage.18
 
 The 
complexity of these children’s illness may explain why their parents felt clinic 
visits had not been of much value in changing their child’s condition.   
Previous studies have indicated financial constraints to be an issue of concern 
to those with epilepsy.26,27 Although 87% of the children in this cohort had 
seizures and required anticonvulsant medications, none of the parents 











a major concern. This finding may be due to the fact that majority (80.6%) of 
the patients in this group were in H0 and H1 income classes and did not 
shoulder the full cost of care for these children as they were entitled to free 
services at the hospital. In addition, half the families (51.6%) receive care 
dependence grants that helped ease the burden of care imposed by TSC. 
 
A statistically significant difference was not detected in the number of 
concerns expressed when those who received a leaflet were compared to 
those who did not receive one during the first visit. The fact that a greater total 
number of concerns were expressed by both groups at the second visit may 
indicate a heightened awareness of problems attributable to TSC as a result 


































A definite diagnosis of TSC can be made for children in South Africa. All 
children seen at The TSC service at the Red Cross Children’s Hospital fulfill 
the diagnostic criteria for TSC. 
 
The clinical profile of the cohort of children seen at the Red Cross Children’s 
Hospital is similar to that of other cohorts described in literature. 
 
Parental understanding of TSC can be improved by provision of written 
information for those with at least a grade eight (secondary school) level of 
education.   
 
Parental understanding of the impact of TSC on their children and their major 
concerns regarding the condition are not associated with the parental level of 
knowledge. 
 
The known duration of a child’s illness has no correlation with the parental 
level of knowledge or the parental perception regarding the value of the TSC 




























• The TSC service at Red Cross Children’s Hospital should formally 
adopt the information leaflet used in this study to help educate parents 
of children with TSC.    
• A significant proportion of parents (42.8%) attending the service have a 
low level of education and their information needs would not be 
sufficiently met by provision of an information leaflet. Group education 
sessions could address this need and clarify difficult concepts 
regarding TSC. 
• Parental education on TSC needs to be continuous throughout the time 
a child attends the service.    
• Parental concerns regarding the future of their children need to be 
addressed. This can be achieved by holding forums where issues that 
include training and placement opportunities, adolescent care and 
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TUBEROUS SCLEROSIS STUDY 
PROFORMA 
Demographic data 
Current Age:            Months                                        Folder No.     
Age at presentation:            months 
Sex:             Male                   female 
Ancestry 
Weight          Kg                   Height              Cm  HC       cm 
Family income classification 
Family history of seizures                Yes           No 




A) Major features                                                  Age at presentation (months)      
Score 
1. Facial angiofibromas 
2. Hypo pigmented macules – Classical > 3 
3. Shagreen patch 
4. Fibrous plaque of forehead or scalp  
5. Cortical tubers 
6. Subependymal nodules 
7. Giant cell astrocytoma 
8. Retinal harmatomas 
9. Cardiac rhabdomyoma 
10. Lymphangiomyomatosis 
11. Renal angiomyolipomas 















B) Minor features                                                             Age at presentation 
13. Relative with T.S 
14. Wedge shaped area of cortical /  
      sub cortical calcification 
15. Multiple sub cortical hypodense areas 
16. Dental pits 
17. Hamartomatous rectal polyps 
18. Bone cysts 
19. Cerebral white matter radial migration lines 
20. Gingival fibromas 
21. Non renal hamartomas 
22. Retinal achromic patch 
23. Confetti skin lesions 
24. Multiple renal cysts 
                         TOTAL NUMBER  
 
Other clinical features                                                    Age at presentation 
1. Seizure Type 
a) Infantile spasms 
b) Generalized Seizures 
c) Partial seizures 
2. Seizure frequency in preceding 3 months 
        / week                         /month 
 
3. Developmental delay 
a) Gross motor 
b) Fine motor 
c) Language 
d) Personal Social 





















5. Neuro – Psychiatric co-morbidities                                          
a) Autism spectrum disorders 
b) Conduct disorders 
c) Oppositional defiant disorder 
 
6.  Learning Institution attended:  (indicate) 
a) Mainstream schooling  
b) Remedial school 
c) Training centre 
d) Special care 
e) Home / not placed 
 
 
7. Renal manifestations 
a) Hematuria 
b) Flank pain 




6. Cardiac manifestations 
a) Arrhythmia 
b) Cardiac failure 
 














9. Other systemic involvement 
a) Related to TSC 
b) Unrelated to TSC 
 
Key conclusions from relevant investigations  
1. EEG 
2. CT scan brain 
3. MRI Brain 
4. ECG 
5. Echocardiogram 





a) First line                                                             Dose 
b) Second line                                                        Dose 
 




3. Surgery   Y/N 
a) Brain 




4. Other interventions 
a) Vagus nerve stimulator 
b) Ketogenic Diet 
 













INFORMATION LEAFLET ON TUBEROUS SCLEROSIS COMPLEX (TSC)   
(Modified from: Tuberous sclerosis alliance web site, www.tsalliance.org  
information for parents.) 
WHAT IS TSC?
The human body is composed of thousands of tiny units called cells. Genes 
are the parts of these cells that direct how the cells themselves work. Genes 
are also the functional units that allow parental features to be passed on to a 
child.  When abnormalities occur in a gene they are called mutations. 
Tuberous sclerosis complex (TSC) is a condition that results from 
abnormalities in the genes that are passed on from a parent to a forming 
fetus.  
   
Tuberous sclerosis complex can be transmitted from a parent to a child 
(genetic inheritance as explained above) or can occur as a new abnormality in 
the genes of a child, also known as a spontaneous genetic mutation.  
Children have a 50 percent chance of inheriting TSC if one of their parents 
has this condition. This means that the possibility that a child shall have the 
condition passed on to them by a parent is the same as that of not inheriting 
that abnormal gene. They may or they may not get the condition.  
At this time, only one of every three TSC cases is known to be inherited. The 
others are believed to be a result of new abnormalities in the genes a child 
has (spontaneous mutation). The cause of these mutations is still not well 
understood.  
You will see the condition referred to both as tuberous sclerosis (TS) and 













What genes are responsible for TSC? 
Two genes have been identified that can cause tuberous sclerosis complex. 
Only one of the genes needs to be affected for TSC to be present. The TSC1 
gene is located on chromosome 9 and is called the hamartin gene. The other 
gene, TSC2, is located on chromosome 16 and is called the tuberin gene.  
If one were to consider a gene to be a word in a sentence, then a 
chromosome can be likened to the sentence that gives a cell instructions on 
what to do and how to do it. If a word is spelt wrongly (mutation) then the 
instruction would be incorrect.  
How does a person develop TSC? 
 Both the TSC1 and TSC2 genes are believed to control the growth of cells in 
the body. When either of these genes is defective, cell growth is not regulated 
and tumors (abnormal growths) occur. The growths are very slow growing and 
occur in many different organs, primarily in the brain, eyes, heart, kidney, skin 
and lungs. The genes also play a role in the early fetal development of the 
brain and skin. 
The disease affects some people severely, while others are so mildly affected 
that it often goes undiagnosed. Some people with TSC experience fits, 
developmental delay, mental retardation and behavioral problems caused by   
growths in the brain.  
However, there are also many people with TSC living independent, healthy 
lives and enjoy challenging professions such as doctors, lawyers, educators 
and researchers. 
How many people have TSC? 
Current estimates place tuberous sclerosis complex-affected births at one in 
6,000. Nearly 1 million people worldwide are known to have TSC. Although 











South Africa, the condition is known to affect all populations with a similar 
frequency. 
If a parent has a mild form of TSC, will their child with TSC also be 
mildly affected? 
People with mild cases of tuberous sclerosis complex can produce a child 
who is more severely affected. In fact, some people are so mildly affected that 
they may only find out they also have TSC after their more severely affected 
child receives a diagnosis of TSC. 
How is TSC diagnosed? 
Diagnosis of tuberous sclerosis complex is currently made following a doctor’s 
examination and various tests. These tests include a wood's Lamp 
examination of the skin to detect changes known to occur in TSC.  MRI and 
CT Scans of the brain are methods used to take detailed images of the brain 
to detect abnormal growths also known as cortical tubers and astrocytomas. 
Similarly renal ultrasound and echocardiogram are images that are created 
using special sound waves that detect abnormal growths in the heart and 
kidney as well as kidney cysts. 
Do the tumors cause cancer? 
The tumors resulting from tuberous sclerosis complex are non-cancerous, but 
may still cause serious problems. Tumors that grow in the brain can block the 
flow of cerebral spinal fluid in the spaces (ventricles) in the brain. This can 
lead to behavior changes, nausea, headaches or other symptoms.  
In the heart, the tumors are usually at their largest at birth, and then decrease 
in size as the individual gets older. These heart tumors, called cardiac 
rhabdomyomas, can cause problems at birth if they are blocking the flow of 
blood or causing abnormal heart beats.  
The tumors in the kidney (renal angiomyolipoma) can become so large they 











remove individual tumors before they get too large and reduce the function of 
healthy kidney tissue.  
Very rarely (less than 2 percent of) individuals with TSC develop malignant 
(cancerous) kidney tumors. 
What is the normal life expectancy of an individual with TSC? 
Most people with TSC will live a normal life span. There can be complications 
in some organs such as the kidneys and brain that can lead to severe 
difficulties and even death if left untreated. To reduce these dangers, people 
with TSC should be monitored throughout their life by their physician for 
potential problems. Thanks to research findings and improved medical 
therapies, people with tuberous sclerosis complex can expect improved health 
care. 
Since there is no cure, what can be done? 
Follow up with early management of complications helps reduce the impact of 
TSC on patients. Advances in research are bringing new and improved 
treatment options. Surgery to remove tumors or stop tumor growth is helping 
to preserve the function of affected organs. Technology is pinpointing the 
exact parts of the brain causing seizures which in some cases can be 
surgically removed. New drugs help control seizures.  
What are the chances that I shall have another child with TSC? 
If you as a parent have TSC, for each child conceived by you there is a 50% 
chance that that child shall have TSC as well. That is it is just as likely that 
they shall have TSC as it is that they shall not have it. If you do not have TSC 
then the chances that another of your children could have TSC are much 
















TUBEROUS SCLEROSIS COMPLEX STUDY INFORMATION LEAFLET 
AND CONSENT FORM  
 
Principal investigator: Dr Pauline Samia  
School of Adolescent and Child Health 
Red Cross Children’s Hospital 
Rondebosch, Cape Town 
Contact number: (073) 638 6000 
 
You are invited to take part in a research study involving parents / carers of 
children who have Tuberous sclerosis complex. We would like to ask for your 
consent. Please take some time to read the information presented here which 
will explain the details of the study. Please ask the study staff or doctor any 
questions about any part of this study that you do not fully understand. It is 
very important that you are fully satisfied that you understand what the 
research entails and how you may be involved.  
Your participation is entirely voluntary. If you are at all uncomfortable with the 
process you may contact me (Dr P Samia) or Dr B Schlegel. You are also free 
to withdraw at any stage, even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at the 
University of Cape Town and will be conducted according to the ethical 
guidelines and principles of the International Declaration of Helsinki, South 
African Guidelines for Good Clinical Practice and Medical Research Council 
(MRC) Ethical Guidelines for Research.  
 
What is this research study all about? 
Research done in other parts of the world indicates that a parent’s knowledge 
regarding their child’s illness influences how they and how well they 
understand the course of the illness and required interventions. Less 
knowledgeable parents are less likely to be compliant with medications, 
investigations and doctor’s appointments. On the other hand adequate 











children. In this study we seek to establish the level of knowledge parents of 
children with Tuberous sclerosis have. We shall in addition establish whether 
provision of written information regarding TSC improves parents’ 
understanding of the condition. We shall do this by asking them a few 
questions regarding their child’s condition as they wait to see the doctor. We 
shall provide half of the parents with an information pamphlet to go read at 
home. At the following visit to see the doctor, we shall ask the same questions 
and compare the results with those obtained at the previous visit. 
 
Children with TSC present in very many different ways. For example some 
children have profound mental disability while others have normal intellect. By 
doing this study we would like to help parents of children with TSC understand 
this condition well and how it affects their individual children. We would like to 
determine if provision of written information would be an effective way to do 
this. 
 
What would participation in this study involve? 
A brief meeting with the study doctor during which you shall be asked a few 
questions that only require verbal answers. 
 
Will you benefit from taking part in this research? 
Yes because you shall have an additional opportunity to understand your 
child’s condition. You shall also contribute to the improvement of the TSC   
service at Red Cross children’s hospital.  
 
Who will have access to your child’s records? 
All information collected will be treated as confidential and protected. If it is 
used in a publication or thesis, the identity of the participant will remain 
anonymous. The only people who will have access to the information 
collected will be Dr’s Pauline Samia, Dr. Birgit Schlegel and  
Prof Jo Wilmshurst. As part of the study the research records may need to be 












Will you be paid to take part in the study and are there any costs 
involved? 
 
No, you will not be paid to take part in the study as information required from 
you shall only be sought when you come to the doctor for your child’s regular 
check up. 
 
Is there anything else you should know or do? 
Please don’t hesitate to contact Dr Pauline Samia at telephone (073) 638 
6000 should you have any further queries or encounter any problems 
You can contact the Committee for Human Research at 021-4066338 (Health 
sciences faculty, Research Ethics Committee, Room E52-24 Groote Schuur 
Hospital, Old Main Building, Observatory, 7925) if you have any concerns or 




By signing below, I………………………………………..consent to take part in 
the research study entitled: Parental knowledge and perceptions of Tuberous 
Sclerosis Complex in children. 
I declare that: 
I have read or had read to me information regarding the study and the 
consent form and I fully understand their contents with which I am 
comfortable. 
I have had a chance to ask questions and all my questions have been 
adequately answered 
I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
I may choose to leave the study at any time and will not be penalized or 
















PARENTAL KNOWLEDGE AND PERCEPTIONS OF TUBEROUS 
SCLEROSIS COMPLEX IN CHILDREN: QUESTIONNAIRE 
 
Child’s Folder number 
Age of parent /legal guardian                        Yrs  
Sex of parent /legal guardian         Female               Male        
Relationship to child:    
Marital status            Married      Single      Separated       Widowed 
Educational level of parent /legal guardian 
Ancestry 
Child’s Current Age                                    Age at presentation to RXH                                               
Duration of Child’s illness 
Source of current information on TSC (specify) 
 
1. What condition/ illness is your child on treatment and or follow up for?                            
.                                                                                                       SCORE                                                                                                                                                       
a) I don’t know                                                                                  0 
b) Seizures                                                                                       1 
c) Skin problem                                                                                1 
d) Behavioural difficulties                                                                 1 
e) Tuberous sclerosis                                                                       4 
 
2. What is the cause of this illness? 
a) I don’t know                                                                                         0 
b) Other  (eg  Bewitchment) please specify                                            0  
- 
-                                                              
c) Infection                                                                                              0  
d) Inherited (It occurs in families, passed on from a parent to a child)    4                                                     
e) Spontaneous (The patient is the first one in a family observed to have 













3. How is a diagnosis of this condition made? 
a) I don’t know                                                                                          0 
b) By physical examination                                                                       2 
c) By full clinical evaluation and investigations.                                        4 
 
4. What body parts or systems do you know are affected by the illness your 
child has? 
a) Brain                                                                                                    4 
b) Skin                                                                                                     4 
c) Kidney                                                                                                 4 
d) Heart                                                                                                   4 
e) Eyes                                                                                                    4 
f) I don’t know                                                                                         0 
g) Other                                                                                                   0 
 
5. What Investigations do you know can be done to diagnose or monitor TSC 
in children? 
a) I don’t know any                                                                                 0 
b) MRI /CT Scan of the brain                                                                 4 
(A detailed “picture” of the brain structure) 
c) Ultrasound of the kidney                                                                    4 
(An image of the structure of the kidney created by special sound waves)  
d) Echocardiogram of the heart                                                               4 
(An image of the structure of the heart created by special sound waves) 
e) EEG (Electroencephalogram: A record of brain wave activity.)        4                                                
f) Woods lamp examination of the skin                                                4 
(A special light used to examine the skin, allowing better detection of 
abnormal areas) 
 
6. Can this illness be cured? 
a) I don’t know                                                                                      0 
b) Yes                                                                                                   0 













7. What help can be offered to children having the condition your child has? 
a) Nothing much.                                                                                  0 
b) Visit the doctor                                                                                 1 
c) Give medications                                                                             1 
d) Address the problems the child has and have  
     regular follow up to look for new problems.                                     4 
 
8. What problems maybe observed in children with TSC? 
a) Seizures / fits                                                              4 
b) Behavioural problems, please specify below             4 
– 
– 
c) Learning difficulties                                                     4 
d) Inability to participate in school /learning activities     4 
e) Inability to participate in social activities                     4 
 
 
9. To what extent has your child’s illness affected the quality of his/her life? 
a) Major negative impact 
b) Some negative effect 
c) No effect. 
 
10. Which issue(s) worry you the most? 
a) Severity of illness 
b) An uncertain future 
c) Cost of medication/ care 
d) Effect of the child’s illness on the family 
e) Effect of the child’s illness on me as a caregiver 
f) Other 
 
11.Your child attends a clinic that is dedicated to provision of service to 












12. Have you learnt about TSC from any other source apart from the 
information given to you at the TSC clinic?   NO   YES (please specify source) 
 
(Ask on second visit) 
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